SCIESCOPUSQ4
GaBI Journal-Generics and Biosimilars Initiative Journal
PRO PHARMA COMMUNICATIONS INT, Belgium
GaBI Journal-Generics and Biosimilars Initiative Journal is an academic journal published by PRO PHARMA COMMUNICATIONS INT (Belgium). Identifiers: ISSN 2033-6403, eISSN 2033-6772. Indexed in SCIE, SCOPUS. Metrics: JIF 0.2, CiteScore 0.7, SJR 0.150, SNIP 0.31. Subject areas: PHARMACOLOGY & PHARMACY. tlooto lists 56 papers from this journal.
CiteScore
0.70
Scopus citation metric
SJR
0.150
SCImago rank
SNIP
0.31
Source normalized impact
Percentage rank
-
JIF percentile rank
Journal profile
- ISSN
- 2033-6403
- eISSN
- 2033-6772
- Abbreviation
- GABI J
- Publisher
- PRO PHARMA COMMUNICATIONS INT
- Country
- Belgium
Web of Science categories
No Web of Science category data available.
Scopus ASJC categories
2709 Drug Guides3611 Pharmacy
Papers in this journal
Recent papers
- Editor’s introduction to the initial issue of the 14th volume of GaBI Journal
2025
- Comment on the article by Reilly MS and McKibbin RD
2025
- An analysis of policy impacts on the price developments of biological medicines after patent expiration
2025
- Biosimilars in oncology: beyond regulation—building confidence through evidence and dialogue
2025
- Therapeutic equivalence of a formulation of purified micronized flavonoid fraction of diosmin/hesperidin 450 mg/50 mg in healthy adults: an open-label, randomized, single-dose, crossover study
2025
Most cited papers
- Pharmacokinetics of Antimicrobials in Obese Children
2013 · 19 citations
- What pricing and reimbursement policies to use for off-patent biologicals? – Results from the EBE 2014 biological medicines policy survey
2015 · 12 citations
- Randomized non-inferiority trial fails to find inferiority switching from infliximab originator to CT-P13 biosimilar
2017 · 9 citations
- Update on US state legislation on biosimilars substitution
2015 · 6 citations
- Interchangeability of biosimilars in the US and around the world
2017 · 5 citations